NIS4® Technology

About Genfit

Founded in 1999, Genfit has established itself as a key player in liver disease R&D, leveraging deep expertise in nuclear receptor biology to develop therapeutics and diagnostics. Its strategy is validated by the Phase 3 success of elafibranor in PBC and the commercial launch of its NIS4® diagnostic. The company is now executing a dual-track strategy of advancing its late-stage asset towards regulatory approval while building a commercial diagnostics business.

Therapeutic Areas